Genetic testing, research and organ donation

Genetic consent and interpretation

Before genetic testing, clarify the clinical question, possible results, limitations and how findings may affect the person and relatives. Diagnostic testing, carrier screening and predictive testing have different purposes. Discuss uncertainty, incidental findings, privacy and current legal/insurance implications through a qualified service when relevant. A variant of uncertain significance is not proof of disease and should not automatically drive major irreversible treatment. Family history and phenotype remain important; a negative panel does not exclude every inherited disorder.

Predictive testing for a serious adult-onset condition needs careful counselling and voluntariness. Do not assume that a relative's wish to know overrides the patient's choices. Testing a child requires an assessment of present benefit, consent and future autonomy rather than routine testing for every adult-onset risk. Direct-to-consumer reports may have limited analytical/clinical validity; confirm through an appropriate accredited clinical pathway before treatment. Discuss reproductive options and family communication without coercion or implying that a genetic finding defines the person's worth.

Relatives, confidentiality and DNA sovereignty

Encourage patients to share actionable hereditary information with relatives, offering support and clear explanation. Confidentiality exceptions require the specific legal framework, risk assessment and expert advice; genetic relatedness is not a blanket permission to release the whole record. Relatives may have a right not to know. Separate the minimum information needed to address risk from unrelated personal details. Document advice and the rationale when difficult competing interests arise rather than applying a memorised slogan.

For research involving Aboriginal and Torres Strait Islander peoples, individual consent is necessary but may not settle collective rights concerning samples, data and knowledge. Engage communities in governance, purpose, collection, storage, access, secondary use, benefit and return of results. DNA sovereignty includes control and self-determination over genetic resources and information, not merely a signed hospital form. Do not assume one community representative speaks for all peoples. Use relevant NHMRC and AIATSIS guidance and community-led processes, including the implications of overseas repositories and future reuse.

Human research

Research requires appropriate ethics review and institutional governance, with a scientifically sound question, fair recruitment and an acceptable risk/benefit balance. The current NHMRC National Statement is the 2025 version, effective from 23 June 2026. Explain randomisation, placebo/control, extra procedures, alternatives and the distinction between research and individual treatment. A clinician-researcher must avoid implying that participation is required to receive ordinary care. Payment should not become undue influence, especially in vulnerable populations.

Consent is an ongoing process, with the ability to withdraw subject to explained limits such as already analysed de-identified data. Capacity, interpreter needs and dependency relationships require attention. Some research can have approved consent modifications, but investigators cannot invent their own waiver because recruitment is difficult. Report adverse events and manage protocol changes through the relevant approvals. Distinguish research from audit or quality improvement using the institution's governance requirements; calling a project an “audit” does not automatically remove ethical obligations.

Organ and tissue donation

Donation decisions require appropriate consent, legal processes and trained teams. Assessment of death follows the accepted neurological or circulatory determination framework; coma, severe disability and a do-not-resuscitate order are not themselves death. Exclude relevant confounders for neurological determination and use the specialist standards. Decisions to limit burdensome treatment should be made independently of organ-retrieval interests. Contact the donation service when potential donation is relevant rather than making unsupported bedside assumptions about eligibility.

Discuss donation sensitively with families, respecting cultural, religious and individual preferences and accurate information about the patient's known wishes. Registration is useful but the lawful consent and practical pathway must still be followed. Tissue donation can have different eligibility/timing from solid-organ donation. Living donation adds the donor's independent welfare, voluntariness and risk; family pressure or financial inducement must be addressed. Transplant allocation should use transparent authorised criteria rather than an individual clinician's personal view of social worth.

Applied ethical reasoning

A patient with a consumer “high-risk mutation” report needs clinical validation and counselling before prophylactic surgery. A researcher proposing future genomic reuse beyond the original consent needs governance and consent assessment, including collective interests where relevant. A deeply unconscious ventilated patient cannot be called brain-dead from appearance alone. A relative offering an organ deserves independent assessment of pressure and risks. Each example tests whether consent, validity and governance are applied to the particular action rather than treated as an administrative signature.

Document the patient's decisions, the scope of testing/use and who will communicate results. Provide a contact for later questions and changes of preference. Clinicians should recognise the limits of their genetic or donation expertise and obtain suitable help, while continuing ordinary care and support. Appropriate referral is an active part of safe practice, not abandonment.

NHMRC National Statement, Indigenous research ethics and DonateLife professional statements.

Review checkpoints

• A genetic variant of uncertain significance is not a confirmed pathogenic diagnosis.
• Indigenous genomic research needs attention to community governance and DNA sovereignty.
• Death determination and donation consent are distinct clinical and legal processes.